Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase ... Read more
A non-invasive test that examines microRNAs — small RNA molecules — in urine may be used to identify aggressive prostate cancers with great accuracy, potentially avoiding unnecessary treatments for ... Read more
Inhibiting the protein BRD4 can stop the migration of castration-resistant prostate cancer cells, regardless of the mechanism causing resistance to treatment, new research has shown. This suggests that BRD4 ... Read more
Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate ... Read more
African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans ... Read more
Black men diagnosed with low-risk prostate cancer are two times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting ... Read more
Pin It on Pinterest